Search Results Search Sort by RelevanceMost Recent Policy Forum Jan 2008 Wellness Programs: Legality, Fairness, and Relevance Laura D. Hermer, JD, LLM Wellness programs and health plan incentives may not be effective means for combating addiction and other lifestyle-related conditions. Virtual Mentor. 2008;10(1):45-48. doi: 10.1001/virtualmentor.2008.10.1.pfor1-0801. Case and Commentary May 2024 Should Antimicrobial Resistance Limit Access to an Organ Transplant? Andrew Courtwright, MD, PhD This article discusses fiduciary obligations transplant programs might have to patients with B cenocepacia. AMA J Ethics. 2024;26(5):E367-372. doi: 10.1001/amajethics.2024.367. Podcast Jul 2024 Author Interview: “How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD?” Dr Katherin M. Duthie joins Ethics Talk to discuss her article, coauthored with Dr Kathryn A. Dong: “How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD?” Case and Commentary Jul 2024 How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD? Kathryn A. Dong, MD, MSc and Katherine M. Duthie, PhD, HEC-C Severe withdrawal, risk of patient-initiated discharge, and some inpatients’ uses of substances prompt questions considered in this commentary. AMA J Ethics. 2024;26(7):E512-519. doi: 10.1001/amajethics.2024.512. Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Current page 8
Policy Forum Jan 2008 Wellness Programs: Legality, Fairness, and Relevance Laura D. Hermer, JD, LLM Wellness programs and health plan incentives may not be effective means for combating addiction and other lifestyle-related conditions. Virtual Mentor. 2008;10(1):45-48. doi: 10.1001/virtualmentor.2008.10.1.pfor1-0801.
Case and Commentary May 2024 Should Antimicrobial Resistance Limit Access to an Organ Transplant? Andrew Courtwright, MD, PhD This article discusses fiduciary obligations transplant programs might have to patients with B cenocepacia. AMA J Ethics. 2024;26(5):E367-372. doi: 10.1001/amajethics.2024.367.
Podcast Jul 2024 Author Interview: “How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD?” Dr Katherin M. Duthie joins Ethics Talk to discuss her article, coauthored with Dr Kathryn A. Dong: “How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD?”
Case and Commentary Jul 2024 How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD? Kathryn A. Dong, MD, MSc and Katherine M. Duthie, PhD, HEC-C Severe withdrawal, risk of patient-initiated discharge, and some inpatients’ uses of substances prompt questions considered in this commentary. AMA J Ethics. 2024;26(7):E512-519. doi: 10.1001/amajethics.2024.512.